|
21 Jul 2020 |
Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial
|
|
20 Jul 2020 |
Connect Biopharma Initiates Phase 2 Clinical Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
|
|
17 Jul 2020 |
ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib
|
|
17 Jul 2020 |
Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results
|
|
17 Jul 2020 |
Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
|
|
16 Jul 2020 |
IDBiologics Announces Nature Publication Highlighting Preclinical Results of Ultra-Potent Monoclonal Antibodies Against SARS-CoV-2
|
|
16 Jul 2020 |
LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer
|
|
16 Jul 2020 |
Adagio Therapeutics Launches With $50M Series A Financing to Advance the Development of Best-in-Class, Broadly Neutralizing Antibodies for Coronavirus Treatment and Prophylaxis
|
|
15 Jul 2020 |
Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients
|
|
15 Jul 2020 |
Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer
|
|
14 Jul 2020 |
TREMFYA® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
|
|
14 Jul 2020 |
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
|
|
14 Jul 2020 |
Revitope And Junshi Biosciences Enter Into Research Collaboration And License Agreement To Explore Next Generation Immunotherapies With Precision-Targeted T-Cell Engaging Antibodies
|
|
14 Jul 2020 |
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
|
|
13 Jul 2020 |
Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China
|
|
13 Jul 2020 |
Biocon’s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients
|
|
13 Jul 2020 |
Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-Stage Ovarian Cancer
|
|
09 Jul 2020 |
Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)
|
|
09 Jul 2020 |
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
|
|
09 Jul 2020 |
FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
|
|
09 Jul 2020 |
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease
|
|
08 Jul 2020 |
Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
|
|
07 Jul 2020 |
In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
|
|
07 Jul 2020 |
Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer
|
|
06 Jul 2020 |
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
|
